PBF-1129 vs TT-4
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: Adenosine A2b receptor · full Non-Small Cell Lung Cancer pipeline
PBF-1129
Developed by Palobiofarma SL
NCT03274479 · Phase 1 · status unknown
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT05234307 (registry estimate)
Reported efficacy
Maximum Tolerated Dose (MTD) of PBF-1129 (28 days): Twenty-one patients received escalating doses of 40 to 320 mg once daily with no dose-limiting toxicities. The most frequent treatment-related adverse events of any grade were lymphocytopenia (n = 8, 38.1%), vomiting (n = 8, 38.1%), anorexia (n = 6, 28.5%) and fatigue (n = 6, 28.5%). Pharmacokinetics were dose-proportional, and plasma concentrations stayed above the 90% maximal inhibitory concentration of A2BAR at 320 mg for 24 h.
Result source: NCT03274479
TT-4
Developed by Alpha Compute Corp
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT04969315 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | PBF-1129 | TT-4 |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
PFS, median
- PBF-1129
- —Not reported
- TT-4
- —Not reported
OS, median
- PBF-1129
- —Not reported
- TT-4
- —Not reported
ORR
- PBF-1129
- —Not reported
- TT-4
- —Not reported
Duration of response, median
- PBF-1129
- —Not reported
- TT-4
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
PBF-1129: no structured comparison results are available for Non-Small Cell Lung Cancer.
TT-4: no structured comparison results are available for Non-Small Cell Lung Cancer.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PBF-1129's landscape · TT-4's landscape